U.S. markets closed

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.83+0.33 (+5.08%)
At close: 04:00PM EDT
6.83 0.00 (0.00%)
After hours: 07:34PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close6.50
Bid6.60 x 1800
Ask7.00 x 1400
Day's Range6.53 - 6.96
52 Week Range5.47 - 12.79
Avg. Volume429,296
Market Cap1.529B
Beta (5Y Monthly)2.77
PE Ratio (TTM)N/A
EPS (TTM)-1.53
Earnings DateNov 14, 2023 - Nov 20, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.92
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CVAC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CureVac N.V.
    Analyst Report: CureVac N.V.CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac’s first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Motley Fool

    Why CureVac Stock Plunged Today

    Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.


    CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

    Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTechRuling on infringement to be provided latest once the validity of the intellectual property rights in suit has ...

  • Reuters

    CORRECTED-German court suspends mRNA patent trial against BioNTech

    A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its U.S. partner Pfizer. The Duesseldorf regional court said it needed further clarification and suspended the case, brought by BioNTech competitor CureVac, pending decisions by the German and the European patent offices on a legal challenge filed by BioNTech. A separate patent infringement case brought by CureVac was previously suspended by the Duesseldorf court because a higher court first needs to review that patent's validity.